Orlowski, Robert Z <br/><br/>
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Sep 2007 
 - 3892-901 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2006.10.5460  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Cardiovascular Diseases--chemically induced<br/>Disease Progression<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Drug Resistance, Neoplasm<br/>Female<br/>Hematologic Diseases--chemically induced<br/>Humans<br/>Incidence<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Neoplasm Recurrence, Local<br/>Polyethylene Glycols--administration & dosage<br/>Pyrazines--administration & dosage